CCXI ChemoCentryx, Inc.

7.04
+0.21  (3.07%)
Previous Close 6.83
Open 6.82
Price To book 6.01
Market Cap 336.55M
Shares 47,805,000
Volume 128,773
Short Ratio 11.07
Av. Daily Volume 216,974

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Partner required to continue with Phase 3 program
Vercirnon CCX282
Crohn's disease
Phase 2 top-line data released Dec 12 2014. Partner required for further development.
CCX140
Diabetic nephropathy
Phase 1b early response data released September 1, 2016. Initial PFS data released January 20, 2017.
CCX872
Non-resectable pancreatic cancer
Phase 2 data presented at ASN Kidney Week - November 17, 10:00 to 2:00 p.m. CT
CCX168
Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3 initiated December 2016.
CCX168
Associated vasculitis (AAV)

Latest News

  1. Coverage initiated on ChemoCentryx by JMP Securities
  2. CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
  3. Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases
  4. ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer
  5. ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco
  6. ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : January 19, 2017
  7. ChemoCentryx Provides Corporate Update Including Development Strategy for Lead Programs in Rare Renal Diseases
  8. ChemoCentryx to Present at the 35th Annual J.P. Morgan Healthcare Conference
  9. ChemoCentryx, Inc. – Value Analysis (NASDAQ:CCXI) : January 3, 2017
  10. ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : January 2, 2017
  11. Vifor Pharma and ChemoCentryx announce expansion of Kidney Health Alliance to include CCX140 to treat renal diseases01
  12. ChemoCentryx Expands Partnership With Vifor Pharma, Licenses CCX140 For Renal Diseases
  13. CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
  14. Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases
  15. Is ChemoCentryx Inc (CCXI) A Stock Worth Buying?
  16. Everyday Health Inc (EVDY), ANSYS, Inc. (ANSS), More: Why You Should Pay Attention To These Stocks
  17. CHEMOCENTRYX, INC. Financials
  18. CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report
  19. Edited Transcript of CCXI earnings conference call or presentation 7-Nov-16 10:00pm GMT
  20. CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi